Commentary on the state-of-the-science conference on the role of active surveillance in the management of men with localized prostate cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 135-139

  Hall, Ingrid J ^a   Richardson, Lisa C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; HUMAN; MEDICAL DOCUMENTATION; MEDICAL HISTORY; MEDICAL RESEARCH; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; WATCHFUL WAITING; BLOOD; MALE; PROSTATE TUMOR; PUBLIC HEALTH SERVICE; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES; WATCHFUL WAITING;

EID: 84871814793     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs040     Document Type: Article

References (9)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012. http://www.cancer.org/acs/groups/content/atepidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed September 25, 2012.
2. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18):1280-1283.
3. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.
4. Andriole GL, Crawford ED, Grubb RL III, et al PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-1329.
6. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-131.
7. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58(6):831-835.
8. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011;29(27):3669-3676.
9. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-ofthe-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156(8):591-595.